People
Andreas Wallnöfer
Andreas Wallnöfer advises ClavystBio and has held senior Roche research and development positions, including cardiovascular and metabolism leadership. His investing career includes BioMedPartners and Jeito Capital. He holds a pharmacology doctorate from Basel and an executive MBA from IMD.
Roles
Neumirna Therapeutics
CurrentIndependent Board Member
Neumirna Therapeutics
CurrentChair of the R&D Committee
Synendos Therapeutics
CurrentClinical and Scientific Advisor
ClavystBio
CurrentAdvisor